Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.
Share this article
LOS ANGELES, March 11, 2021 /PRNewswire/ The International Myeloma Foundation (IMF) today launched a multiyear
, multidisciplinary initiative called M-Power Charlotte, designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the African-American community. To that end, the IMF is working with Atrium Health Levine Cancer Institute s Disparities & Outreach program in Charlotte, NC, to enlist local leaders and healthcare professionals in promoting increased knowledge about this treatable but little-known disease.
Launched by the International Myeloma Foundation, the M-Power Charlotte initiative is designed to empower people to change the course of myeloma by removing barriers to early diagnosis and treatment in the African-American community.